Understanding Targeted Sequencing Next-Generation Sequencing

Since its launch in 2012, Ion AmpliSeq targeted sequencing technology has seen broad global adoption and resulted in the publication of greater than 140 peer-reviewed publications. Applications span such studies as investigating phenovariance in mice1, assessing gene copy number alterations2, and defining genetic changes associated with lung cancer3 research.

Researchers are not only using Ion AmpliSeq technology for less challenging research samples where available sample quantity and quality are not limiting, such as cell culture or fresh-frozen tissues, but also seeing tremendous success with challenging sample types, such as formalin-fixed paraffin-embedded (FFPE) tissue, achieved samples from fine needle aspirates, and cell-free DNA extracted from blood (cfDNA).

Analysis of FFPE tumor samples
Formalin-fixed paraffin-embedded (FFPE) samples are challenging to work with. Dr. Nicole Pfarr discubrsses her experience with Ion AmpliSeq Panels on the Ion PGM System. (They currently use eight panels, both standard and custom).